ELISA

The HPV33 E7/pRb Binding Assay Kit uses a rapid, simple, and sensitive method to characterize the binding affinity between HPV type 33 E7 oncoprotein and its receptor Retinoblastoma in the presence of potential inhibitors within 4 hours. 4-8 week development phase.

The HPV33 E7/pRb Binding Assay Kit uses a rapid, simple, and sensitive method to characterize the binding affinity between HPV type 33 E7 oncoprotein and its receptor Retinoblastoma in the presence of potential inhibitors within 4 hours. 4-8 week development phase.

The HPV33 E7/pRb Binding Assay Kit uses a rapid, simple, and sensitive method to characterize the binding affinity between HPV type 33 E7 oncoprotein and its receptor Retinoblastoma in the presence of potential inhibitors within 4 hours. 4-8 week development phase.

The HPV33 L1/ITGA6-ITGB4 Binding Assay Kit uses a rapid, simple, and sensitive method to characterize the binding affinity between HPV type 33 major capsid protein and its receptor ITGA6-ITGB4 dimer in the presence of potential inhibitors within 4 hours. 4-8 week development phase.

The HPV33 L1/ITGA6-ITGB4 Binding Assay Kit uses a rapid, simple, and sensitive method to characterize the binding affinity between HPV type 33 major capsid protein and its receptor ITGA6-ITGB4 dimer in the presence of potential inhibitors within 4 hours. 4-8 week development phase.

The HPV33 L1/ITGA6-ITGB4 Binding Assay Kit uses a rapid, simple, and sensitive method to characterize the binding affinity between HPV type 33 major capsid protein and its receptor ITGA6-ITGB4 dimer in the presence of potential inhibitors within 4 hours. 4-8 week development phase.

The HPV33 L1/Laminin-332 Binding Assay Kit uses a rapid, simple, and sensitive method to characterize the binding affinity between HPV type 33 major capsid protein and its receptor Laminin 332 in the presence of potential inhibitors within 4 hours. 4-8 week development phase.

The HPV33 L1/Laminin-332 Binding Assay Kit uses a rapid, simple, and sensitive method to characterize the binding affinity between HPV type 33 major capsid protein and its receptor Laminin 332 in the presence of potential inhibitors within 4 hours. 4-8 week development phase.

The HPV33 L1/Laminin-332 Binding Assay Kit uses a rapid, simple, and sensitive method to characterize the binding affinity between HPV type 33 major capsid protein and its receptor Laminin 332 in the presence of potential inhibitors within 4 hours. 4-8 week development phase.